SCHEMBL3250340

SCHEMBL3250340

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)Nc4cccc(OC)c4)cc3c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
HSD17B10 Q99714 3/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
HPGD P15428 3/20 0.55
ESR1 P03372 1/20 0.55
MAPK1 P28482 1/20 0.55
POLB P06746 11/20 0.54
TDP1 Q9NUW8 7/20 0.54
MAPT P10636 9/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
LMNA P02545 4/20 0.53
GAA P10253 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
THRB P10828 2/20 0.53
TP53 P04637 5/20 0.53
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247530 0.93 HSD17B10 (0.48) ALDH1A1HSD17B10L3MBTL1HPGDESR1
SCHEMBL3254167 0.91 MAPT (0.51) ALDH1A1HSD17B10L3MBTL1HPGDESR1
SCHEMBL3250865 0.91 HSD17B10 (0.50) ALDH1A1HSD17B10L3MBTL1HPGDMAPK1
SCHEMBL3249958 0.90 MAPT (0.50) ALDH1A1HSD17B10L3MBTL1HPGDESR1
SCHEMBL3254789 0.90 PKM (0.51) ALDH1A1HSD17B10HPGDMAPK1POLB
SCHEMBL3253198 0.89 MAPT (0.49) ALDH1A1HSD17B10L3MBTL1HPGDESR1
SCHEMBL3254038 0.89 BRD4 (0.55) ALDH1A1HSD17B10L3MBTL1HPGDESR1
SCHEMBL3244659 0.89 POLB (0.57) ALDH1A1HSD17B10L3MBTL1HPGDESR1
SCHEMBL3249389 0.87 ALDH1A1 (0.52) ALDH1A1HSD17B10L3MBTL1HPGDESR1
SCHEMBL3244722 0.86 PKM (0.56) ALDH1A1HSD17B10L3MBTL1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 ALDH1A1 3830/4885HSD17B10 3847/4885L3MBTL1 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.